Erythropoietins should be used according to guidelines

The Lancet Oncology

Volumn 9, Issue 5, 2008, Pages 412-413

  Aapro, Matti S ^a   Birgegård, Gunnar ^b   Bokemeyer, Carsten ^c   Cornes, Paul ^d   Foubert, Jan ^e   Gascon, Pere ^f   Glaspy, John ^g   Hellström Lindberg, Eva ^h   Link, Hartmut ⁱ   Ludwig, Heinz ^j   Österborg, Anders ^h   Repetto, Lazzaro ^k   Soubeyran, Pierre ^l  

^a CLINIQUE DE GENOLIER   (Switzerland)

^b UPPSALA UNIVERSITY   (Sweden)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

^e Erasmus High School   (Belgium)

^f HOSPITAL CLÍNIC   (Spain)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h KAROLINSKA INSTITUTE   (Sweden)

ⁱ Westpfalz Clinic   (Germany)

^j WILHELMINEN HOSPITAL   (Austria)

^k INRCA   (Italy)

^l INSTITUT BERGONIÉ   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ERYTHROPOIETIN; HEMOGLOBIN; HEPARIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG APPROVAL; DRUG FATALITY; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG LABELING; DRUG SAFETY; EVIDENCE BASED MEDICINE; HEMOGLOBIN DETERMINATION; HUMAN; LETTER; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; QUANTITATIVE STUDY; RISK BENEFIT ANALYSIS; THROMBOEMBOLISM;

ANEMIA; ANTINEOPLASTIC AGENTS; DRUG APPROVAL; DRUG LABELING; ERYTHROPOIETIN; GUIDELINE ADHERENCE; HEMATINICS; HUMANS; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 42949089483     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(08)70115-3     Document Type: Letter

References (10)

1. The Lancet Oncology. Erythropoietin analogues: an unnecessary class of drugs. Lancet Oncol 9 (2008) 81
2. Nowrousian M., Dunst J., and Vaupel P. Erythropoietin-stimulating agents: favorable safety profile when used as indicated. Strahlenther Onkol 184 (2008) 121-136
3. Bokemeyer C., Aapro M., Courdi A., et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 43 (2007) 258-270
4. EORTC guidelines on the use of erythropoietin.http://www.cancerworld.org/CancerWorld/eventDetail.aspx?i d_sito=1&id_stato=1&id=1795 (accessed April 14th, 2008).
5. Wilson J., Yao G., Rafferty J., et al. A systematic review and economic evaluation of epoetin alfa, epoetin beta and darbepoetin alfa in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess 11 (2007) 1-202
6. Seidenfeld J., Piper M., Bohlius J., et al. Comparative effectiveness of epoetin and darbepoetin for managing anemia in patients undergoing cancer treatment. http://effectivehealthcare.ahrq.gov/repFiles/EPO%20Final.pdf (accessed April 14, 2008).
7. Rizzo J., Somerfield M., Hagerty K., et al. Clinical practice guideline update of the use of epoetin and darbepoetin American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 26 (2008) 132-149
8. Aapro M., Scherhag A., and Burger H. Effect of treatment with epoetin beta on survival, tumour progression and thromboembolic events in patients with cancer: an updated meta-analysis of 12 randomized controlled studies Including 2301 patients. Br J Cancer (2008) (in press).
9. Bennett C., Silver S., Djulbegovic B., et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 299 (2008) 914-924
10. Sinclair A., Rogers N., Busse L., et al. Erythropoietin receptor transcription is neither elevated nor predictive of surface expression in human tumour cells. Br J Cancer 98 (2008) 1059-1067